Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2023 | Improving transplantation outcomes in patients with active AML: current approaches & future outlooks

Edmund Waller • 8 Sep 2023
SOHO 2023
Acute Myeloid Leukemia Leukemia Gilteritinib

Edmund Waller, MD, PhD, FACP, Winship Cancer Institute of Emory University, Atlanta, GA, discusses the role of allogeneic stem cell transplantation (alloSCT) in patients with acute myeloid leukemia (AML), and further discusses advances that have been made in this space, including the use of post-transplant gilteritinib. This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Stock ownership in Cambium Oncology

More from Edmund Waller

1:12
Managing GvHD in patients undergoing SCT
Edmund Waller • 8 Sep 2023
1:46
Optimizing conditioning regimens in patients with AML undergoing alloSCT
Edmund Waller • 8 Sep 2023
4:18
Duvelisib in CAR T-cell therapy for CLL
Edmund Waller • 1 Sep 2020
5:01
PORTIA: tisagenlecleucel and pembrolizumab in R/R DLBCL
Edmund Waller • 23 Aug 2020

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals